Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women.

[1]  K. Huang,et al.  Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors , 2001, Menopause.

[2]  D. Wagner,et al.  Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. , 2001, Blood.

[3]  S. Khosla,et al.  Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. , 2001, The Journal of clinical endocrinology and metabolism.

[4]  M. Taskinen,et al.  Effects of Oral and Transdermal Estrogen Replacement Therapy on Markers of Coagulation, Fibrinolysis, Inflammation and Serum Lipids and Lipoproteins in Postmenopausal Women , 2001, Thrombosis and Haemostasis.

[5]  A. Gottsäter,et al.  Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. , 2001, Journal of internal medicine.

[6]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[7]  J. Sixma,et al.  Platelet adhesion to collagen in healthy volunteers is influenced by variation of both α2β1 density and von Willebrand factor , 2000 .

[8]  H. Arnesen,et al.  Reduced Expression of Endothelial Cell Markers after Long-term Transdermal Hormone Replacement Therapy in Women with Coronary Artery Disease , 2000, Thrombosis and Haemostasis.

[9]  H. Teede,et al.  Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[10]  P. Sandset,et al.  The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study. , 2000, Thrombosis research.

[11]  O. Schiraldi,et al.  Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C. , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[12]  L. Bouter,et al.  von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[13]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[14]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[15]  C. Stehouwer,et al.  Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. , 1999, Fertility and sterility.

[16]  L. Kuller,et al.  Hormone replacement therapy, inflammation, and hemostasis in elderly women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[17]  J. Jespersen,et al.  Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. , 1999, American journal of obstetrics and gynecology.

[18]  P. Mannucci,et al.  von Willebrand factor: a marker of endothelial damage? , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[19]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[20]  E. Vicaut,et al.  Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. , 1998, Circulation.

[21]  L. Rabbani,et al.  Percutaneous interventions alter the hemostatic profile of patients with unstable versus stable angina. , 1997, Journal of the American College of Cardiology.

[22]  M. Aiach,et al.  Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[23]  A. Blann,et al.  Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease , 1997, European journal of clinical investigation.

[24]  A. Blann,et al.  Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. , 1997, American heart journal.

[25]  A. Blann,et al.  von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. , 1997, Atherosclerosis.

[26]  D. Mancini,et al.  Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients. , 1997, The American journal of cardiology.

[27]  A. Wakatsuki,et al.  Effect of Estrogen on the Size of Low‐Density Lipoprotein Particles in Postmenopausal Women , 1997, Obstetrics and gynecology.

[28]  R. Cannon,et al.  Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. , 1997, The New England journal of medicine.

[29]  J. Barrett,et al.  von Willebrand Factor and Factor VIII: C in Acute Cerebrovascular Disease , 1997, Thrombosis and Haemostasis.

[30]  A. Donker,et al.  Endothelial dysfunction and pathogenesis of diabetic angiopathy. , 1997, Cardiovascular research.

[31]  R. Cannon,et al.  Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. , 1997, The New England journal of medicine.

[32]  J. Hsia,et al.  Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors. , 1996, American Journal of Cardiology.

[33]  V. Salomaa,et al.  Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1996, Circulation.

[34]  C. Lindoff,et al.  Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease. , 1996, Maturitas.

[35]  M. Tortajada,et al.  The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. , 1995, American journal of obstetrics and gynecology.

[36]  W. Richter,et al.  Hemostatic factors and the risk of myocardial infarction. , 1995, The New England journal of medicine.

[37]  D. Levy,et al.  Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. , 1995, Circulation.

[38]  A. Hamsten.  Hemostatic function and coronary artery disease. , 1995, The New England journal of medicine.

[39]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[40]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[41]  G. Silfverstolpe,et al.  The Effects of Transdermal Estradiol and Oral Conjugated Estrogens on Haemostasis Variables , 1994, Thrombosis and Haemostasis.

[42]  J. Gauldie,et al.  The acute phase response. , 1994, Immunology today.

[43]  L. Guize,et al.  Haemostatic Variables and Menopausal Status: Influence of Hormone Replacement Therapy , 1993, Thrombosis and Haemostasis.

[44]  L. Tavazzi,et al.  The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[45]  A. Bostom,et al.  Postmenopausal estrogen therapy and cardiovascular disease. , 1992, The New England journal of medicine.

[46]  J. Jansson,et al.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. , 1991, British heart journal.

[47]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.

[48]  L. Mattsson,et al.  Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. , 1991, British journal of obstetrics and gynaecology.

[49]  M. Cortellaro,et al.  Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in posimenopausal women , 1991 .

[50]  L. Mattsson,et al.  Haemostatic changes during continuous oestradiolprogestogen treatment of postmenopausal women , 1990 .

[51]  W. Chandler,et al.  Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. , 1990, Blood.

[52]  Y. Vandekerckhove,et al.  Plasma tissue plasminogen activator levels in patients with coronary heart disease. , 1988, Thrombosis research.

[53]  V. Ravnikar.  Compliance with hormone therapy. , 1987, American journal of obstetrics and gynecology.

[54]  W. Kannel,et al.  Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. , 1986, American heart journal.

[55]  A. Paganini-Hill,et al.  Estrogen Replacement Therapy and Coronary Heart Disease , 1983 .

[56]  R. Wolf,et al.  Cytokine–Induced Alteration of Platelet and Hemostatic Function , 1996, Stem cells.

[57]  A. Schindler,et al.  [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens]. , 1995, Zentralblatt fur Gynakologie.

[58]  J. V. van Wersch,et al.  The Effect of Two Regimens of Hormone Replacement Therapy on the Haemostatic Profile in Postmenopausal Women , 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[59]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .

[60]  M. Cortellaro,et al.  Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. , 1991, Thrombosis research.